FIRST-INHUMAN STUDY OF SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IRAK1/4 INHIBITOR R835 IN HEALTHY SUBJECTS

被引：2

作者：

Yan, L. ^{[1
]}

Tong, S. ^{[1
]}

Absalom, A. ^{[2
]}

Daas, I. D. ^{[3
]}

Park, G. ^{[1
]}

Taylor, V. ^{[1
]}

Chow, D. ^{[1
]}

Lee, M. ^{[1
]}

Zheng, H. ^{[1
]}

Chow, A. ^{[1
]}

机构：

[1] Rigel Pharmaceut Inc, San Francisco, CA USA

[2] Univ Med Ctr Groningen, Groningen, Netherlands

[3] QPS Netherlands BV, Groningen, Netherlands

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷

关键词：

D O I：

10.1136/annrheumdis-2020-eular.4590

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

THU0219

引用

页码：332 / 332

页数：1

共 50 条

[31] Safety, pharmacokinetics, and pharmacodynamics of anti-IL-4Rα antibody SHR-1819 in healthy subjects: A randomized, controlled phase I study
Li, Na
Shakib, Sepehr
Qian, Weilin
Yao, Xiaoyan
Li, Puyuan
Nip, Tsz Keung
Bai, Xiaoyan
Shen, Kai
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (04):
[32] Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects
Cao, Ying Jun
Sawamoto, Taiji
Valluri, Udaya
Cho, Kathy
Lewand, Michaelene
Swan, Suzanne
Lasseter, Kenneth
Matson, Mark
Holman, John, Jr.
Keirns, James
Zhu, Tong
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (06): : 435 - 449
[33] Safety, Pharmacokinetics, and Pharmacodynamics of TD-0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects
Kanodia, Jitendra
Lo, Arthur
Baldwin, R. Michael
Colley, Ken
Zhou, Kefei
Bourdet, David L.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1307 - 1315
[34] PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF NC-2500, A NOVEL XANTHINE OXIDOREDUCTASE INHIBITOR, IN HEALTHY JAPANESE MALE SUBJECTS
Hirano, M.
Kobayashi, S.
Miyayama, E.
Ohtal, T.
Yamamoto, M.
Yamakawa, T.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1634 - 1635
[35] Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects
Cilla, DD
Whitfield, LR
Gibson, DM
Sedman, AJ
Posvar, EL
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (06) : 687 - 695
[36] A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects
Ahmadi, Ali R.
Atiee, George
Chapman, Bart
Reynolds, Laurie
Sun, John
Cameron, Andrew M.
Wesson, Russell N.
Burdick, James F.
Sun, Zhaoli
CELL REPORTS MEDICINE, 2023, 4 (09)
[37] Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Tadao Akizawa
Ryutaro Shimazaki
Masanari Shiramoto
Masafumi Fukagawa
Clinical Drug Investigation, 2018, 38 : 945 - 954
[38] Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Akizawa, Tadao
Shimazaki, Ryutaro
Shiramoto, Masanari
Fukagawa, Masafumi
CLINICAL DRUG INVESTIGATION, 2018, 38 (10) : 945 - 954
[39] Use of R191, potent and selective IRAK1/4 kinase inhibitor, in treatment of hematologic malignancies
Markovtsov, V.
Lamagna, C.
Chan, M.
Yi, S.
Young, C.
Forances, R.
Siu, S.
Braselmann, S.
Li, H.
Singh, R.
Park, G.
Masuda, E.
Taylor, V.
Payan, D. G.
EUROPEAN JOURNAL OF CANCER, 2016, 54 : S22 - S23
[40] First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects
Zhou, Jin
Limsakun, Tharin
Yin, Ophelia
Warren, Vance
Zamora, Cynthia
Atiee, George
Kochan, Jarema
Pav, Joseph
Kobayashi, Fumiaki
Vashi, Vijay
Dishy, Victor
JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (12): : 1669 - 1677

← 1 2 3 4 5 →